Press Release: ESCMID: Sanofi’s Nuvaxovid COVID-19 vaccine showed better tolerability than mNEXSPIKE in head-to-head study
ESCMID: Sanofi's Nuvaxovid COVID-19 vaccine showed better tolerability than mNEXSPIKE in head-to-head…
ESCMID Global: Maternal RSV vaccination cuts infant hospitalisation risk by over 80%, major UKHSA study finds
MUNICH, April 18, 2026 /PRNewswire/ -- The largest real-world study of its…
BioVersys to Present Data on Clinical and Preclinical Pipeline Programs at ESCMID Global 2026
April 15, 2026 01:00 ET | Source: BioVersys BASEL, Switzerland, April 15,…
